Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Résultat de la recherche
2 recherche sur le mot-clé 'sensory gating'
Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche Faire une suggestion
Normal P50 Gating in Children with Autism, Yet Attenuated P50 Amplitude in the Asperger Subcategory / Gitte Falcher MADSEN in Autism Research, 8-4 (August 2015)
[article]
Titre : Normal P50 Gating in Children with Autism, Yet Attenuated P50 Amplitude in the Asperger Subcategory Type de document : Texte imprimé et/ou numérique Auteurs : Gitte Falcher MADSEN, Auteur ; Niels BILENBERG, Auteur ; Jens Richardt MØLLEGAARD JEPSEN, Auteur ; Birte GLENTHØJ, Auteur ; Cathriona CANTIO, Auteur ; Bob ORANJE, Auteur Article en page(s) : p.371-378 Langues : Anglais (eng) Mots-clés : autism spectrum disorders P50 sensory gating children auditory processing Index. décimale : PER Périodiques Résumé : Autism spectrum disorders (ASD) and schizophrenia are separate disorders, but there is evidence of conversion or comorbid overlap. The objective of this paper was to explore whether deficits in sensory gating, as seen in some schizophrenia patients, can also be found in a group of ASD children compared to neurotypically developed children. An additional aim was to investigate the possibility of subdividing our ASD sample based on these gating deficits. In a case–control design, we assessed gating of the P50 and N100 amplitude in 31 ASD children and 39 healthy matched controls (8–12 years) and screened for differences between groups and within the ASD group. We did not find disturbances in auditory P50 and N100 filtering in the group of ASD children as a whole, nor did we find abnormal P50 and N100 amplitudes. However, the P50 amplitude to the conditioning stimulus was significantly reduced in the Asperger subgroup compared to healthy controls. In contrast to what is usually reported for patients with schizophrenia, we found no evidence for sensory gating deficits in our group of ASD children taken as a whole. However, reduced P50 amplitude to conditioning stimuli was found in the Asperger group, which is similar to what has been described in some studies in schizophrenia patients. There was a positive correlation between the P50 amplitude of the conditioning stimuli and anxiety score in the pervasive developmental disorder not otherwise specified group, which indicates a relation between anxiety and sensory registration in this group. Autism Res 2015, 8: 371–378. © 2015 International Society for Autism Research, Wiley Periodicals, Inc. En ligne : http://dx.doi.org/10.1002/aur.1452 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=268
in Autism Research > 8-4 (August 2015) . - p.371-378[article] Normal P50 Gating in Children with Autism, Yet Attenuated P50 Amplitude in the Asperger Subcategory [Texte imprimé et/ou numérique] / Gitte Falcher MADSEN, Auteur ; Niels BILENBERG, Auteur ; Jens Richardt MØLLEGAARD JEPSEN, Auteur ; Birte GLENTHØJ, Auteur ; Cathriona CANTIO, Auteur ; Bob ORANJE, Auteur . - p.371-378.
Langues : Anglais (eng)
in Autism Research > 8-4 (August 2015) . - p.371-378
Mots-clés : autism spectrum disorders P50 sensory gating children auditory processing Index. décimale : PER Périodiques Résumé : Autism spectrum disorders (ASD) and schizophrenia are separate disorders, but there is evidence of conversion or comorbid overlap. The objective of this paper was to explore whether deficits in sensory gating, as seen in some schizophrenia patients, can also be found in a group of ASD children compared to neurotypically developed children. An additional aim was to investigate the possibility of subdividing our ASD sample based on these gating deficits. In a case–control design, we assessed gating of the P50 and N100 amplitude in 31 ASD children and 39 healthy matched controls (8–12 years) and screened for differences between groups and within the ASD group. We did not find disturbances in auditory P50 and N100 filtering in the group of ASD children as a whole, nor did we find abnormal P50 and N100 amplitudes. However, the P50 amplitude to the conditioning stimulus was significantly reduced in the Asperger subgroup compared to healthy controls. In contrast to what is usually reported for patients with schizophrenia, we found no evidence for sensory gating deficits in our group of ASD children taken as a whole. However, reduced P50 amplitude to conditioning stimuli was found in the Asperger group, which is similar to what has been described in some studies in schizophrenia patients. There was a positive correlation between the P50 amplitude of the conditioning stimuli and anxiety score in the pervasive developmental disorder not otherwise specified group, which indicates a relation between anxiety and sensory registration in this group. Autism Res 2015, 8: 371–378. © 2015 International Society for Autism Research, Wiley Periodicals, Inc. En ligne : http://dx.doi.org/10.1002/aur.1452 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=268 Brief Report: Initial Trial of Alpha7-Nicotinic Receptor Stimulation in Two Adult Patients with Autism Spectrum Disorder / Ann OLINCY in Journal of Autism and Developmental Disorders, 46-12 (December 2016)
[article]
Titre : Brief Report: Initial Trial of Alpha7-Nicotinic Receptor Stimulation in Two Adult Patients with Autism Spectrum Disorder Type de document : Texte imprimé et/ou numérique Auteurs : Ann OLINCY, Auteur ; Audrey BLAKELEY-SMITH, Auteur ; Lynn JOHNSON, Auteur ; William R. KEM, Auteur ; Robert FREEDMAN, Auteur Article en page(s) : p.3812-3817 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder Attention Sensory gating Receptors nicotinic Index. décimale : PER Périodiques Résumé : Abnormalities in CHRNA7, the alpha7-nicotinic receptor gene, have been reported in autism spectrum disorder. These genetic abnormalities potentially decrease the receptor’s expression and diminish its functional role. This double-blind, placebo-controlled crossover study in two adult patients investigated whether an investigational receptor-specific partial agonist drug would increase the inhibitory functions of the gene and thereby increase patients’ attention. An electrophysiological biomarker, P50 inhibition, verified the intended neurobiological effect of the agonist, and neuropsychological testing verified a primary cognitive effect. Both patients perceived increased attention in their self-ratings. Alpha7-nicotinic receptor agonists, currently the target of drug development in schizophrenia and Alzheimer Disease, may also have positive clinical effects in autism spectrum disorder. En ligne : http://dx.doi.org/10.1007/s10803-016-2890-6 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=297
in Journal of Autism and Developmental Disorders > 46-12 (December 2016) . - p.3812-3817[article] Brief Report: Initial Trial of Alpha7-Nicotinic Receptor Stimulation in Two Adult Patients with Autism Spectrum Disorder [Texte imprimé et/ou numérique] / Ann OLINCY, Auteur ; Audrey BLAKELEY-SMITH, Auteur ; Lynn JOHNSON, Auteur ; William R. KEM, Auteur ; Robert FREEDMAN, Auteur . - p.3812-3817.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 46-12 (December 2016) . - p.3812-3817
Mots-clés : Autism spectrum disorder Attention Sensory gating Receptors nicotinic Index. décimale : PER Périodiques Résumé : Abnormalities in CHRNA7, the alpha7-nicotinic receptor gene, have been reported in autism spectrum disorder. These genetic abnormalities potentially decrease the receptor’s expression and diminish its functional role. This double-blind, placebo-controlled crossover study in two adult patients investigated whether an investigational receptor-specific partial agonist drug would increase the inhibitory functions of the gene and thereby increase patients’ attention. An electrophysiological biomarker, P50 inhibition, verified the intended neurobiological effect of the agonist, and neuropsychological testing verified a primary cognitive effect. Both patients perceived increased attention in their self-ratings. Alpha7-nicotinic receptor agonists, currently the target of drug development in schizophrenia and Alzheimer Disease, may also have positive clinical effects in autism spectrum disorder. En ligne : http://dx.doi.org/10.1007/s10803-016-2890-6 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=297